tailieunhanh - Báo cáo sinh học: " Biochemical prevention and treatment of viral infections – A new paradigm in medicine for infectious diseases"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Biochemical prevention and treatment of viral infections – A new paradigm in medicine for infectious diseases | Virology Journal BioMed Central Review Open Access Biochemical prevention and treatment of viral infections - A new paradigm in medicine for infectious diseases Hervé Le Calvez 1 Mang Yu2 and Fang Fang2 Address 1Abgent Inc. 6310 Nancy Ridge Drive Suite 106 San Diego CA 92121 USA and 2NexBio Inc. 6330 Nancy Ridge Drive Suite 105 San Diego CA 92121 USA Email Hervé Le Calvez - lecalvez@ Mang Yu - myu@ Fang Fang - ffang@ Corresponding author Published 23 November 2004 Received 10 November 2004 Accepted 23 November 2004 Virology Journal 2004 1 12 doi 1743-422X-1-12 This article is available from http content 1 1 12 2004 Le Calvez et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract For two centuries vaccination has been the dominating approach to develop prophylaxis against viral infections through immunological prevention. However vaccines are not always possible to make are ineffective for many viral infections and also carry certain risk for a small yet significant portion of the population. In the recent years FDA s approval and subsequent market acceptance of Synagis a monoclonal antibody indicated for prevention and treatment of respiratory syncytial virus RSV has heralded a new era for viral infection prevention and treatment. This emerging paradigm herein designated Biochemical Prevention and Treatment currently involves two aspects 1 preventing viral entry via passive transfer of specific protein-based anti-viral molecules or host cell receptor blockers 2 inhibiting viral amplification by targeting the viral mRNA with anti-sense DNA ribozyme or RNA interference RNAi . This article summarizes the current status of this field. Introduction A landmark in the